Why Eli Lilly Stock Climbed Today

Eli Lilly's stock rose 4.86% following strong second-quarter earnings driven by surging sales of its obesity drugs Mounjaro and Zepbound, which grew 91% and 44% respectively. The company reported Q2 revenue of $23 billion (up 48% YoY) and adjusted net income of $7.5 billion, exceeding Wall Street expectations. Management raised its full-year revenue guidance to $85-87 billion and is investing profits into pipeline development through strategic acquisitions.